Gland Pharma Ltd

Gland Pharma Limited announced the appointment of Mr. Ajay Sahni as Chief Executive Officer of Gland Pharma International Pte. Ltd., a wholly-owned subsidiary, effective November 2, 2026, and he will also be responsible for Cenexi, a wholly-owned step-down subsidiary, reporting to the CEO of Gland Pharma Limited.

Gland Pharma Ltd gained for a fifth straight session today. The stock is quoting at Rs 3081.9, up 0.24% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.72% on the day, quoting at 23102.8. The Sensex is at 74677.67, up 0.71%. Gland Pharma Ltd has gained around 7.22% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 3.43% in last one month and is currently quoting at 26710.8, up 1.88% on the day. The volume in the stock stood at 89853 shares today, compared to the daily average of 3.98 lakh shares in last one month.The PE of the stock is 35.92 based on TTM earnings ending June 26.

Gland Pharma Ltd is up for a third straight session today. The stock is quoting at Rs 3015.2, up 1.85% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.19% on the day, quoting at 22705.75. The Sensex is at 73339.6, down 0.35%. Gland Pharma Ltd has gained around 0.85% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has gained around 1.54% in last one month and is currently quoting at 26267.25, up 0.96% on the day. The volume in the stock stood at 1.19 lakh shares today, compared to the daily average of 4.37 lakh shares in last one month.The PE of the stock is 34.6 based on TTM earnings ending June 26.

Gland Pharma Ltd fell for a fifth straight session today. The stock is quoting at Rs 2833.6, down 0.59% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.24% on the day, quoting at 22406.15. The Sensex is at 72532.22, down 0.98%.Gland Pharma Ltd has eased around 2.2% in last one month.Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has eased around 7.21% in last one month and is currently quoting at 25596.65, down 2.02% on the day. The volume in the stock stood at 2.88 lakh shares today, compared to the daily average of 4.04 lakh shares in last one month.The PE of the stock is 33.4 based on TTM earnings ending June 26.

Gland Pharma Limited will hold a board meeting on Friday, November 06, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, and will host an investor/analyst call at 18:30 Hrs (IST) on the same day. The trading window, previously closed from Thursday, October 01, 2026, will reopen on Monday, November 09, 2026, in compliance with SEBI regulations.

Gland Pharma Limited submitted to the Bombay Stock Exchange and National Stock Exchange a confirmation certificate dated October 3, 2026, received from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, regarding the dematerialization of securities for the quarter ended September 30, 2026.

Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 3141.1, up 4.49% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.53% on the day, quoting at 22655.35. The Sensex is at 72816.45, down 0.34%. Gland Pharma Ltd has added around 6.14% in last one month. Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has added around 1.4% in last one month and is currently quoting at 26549.6, down 0.17% on the day. The volume in the stock stood at 8.23 lakh shares today, compared to the daily average of 4.76 lakh shares in last one month.The PE of the stock is 35.13 based on TTM earnings ending June 26.

Gland Pharma Limited informed the BSE Limited and National Stock Exchange of India Limited that the trading window for dealing in securities of the company will be closed from Thursday, October 1, 2026, until 48 hours after the declaration of the un-audited financial results for the quarter and half year ending September 30, 2026.

Gland Pharma Limited announced that its board approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. ("Gland US") from Gland Pharma International Pte. Ltd., for a cash consideration of USD 5,001,208. The acquisition, expected to be completed by October 31, 2026, will make Gland US a direct wholly-owned subsidiary of Gland Pharma Limited, streamlining the corporate structure and removing multiple layers. Gland US, incorporated in March 2022, is involved in the marketing and distribution of pharmaceutical products and had a turnover of USD 87,342 for the fiscal year ending March 31, 2025, and USD 4,83,808 for the fiscal year ending March 31, 2024.

Gland Pharma Limited announced that its board approved the acquisition of 100% of the equity share capital of Gland Pharma USA Inc. from Gland Pharma International Pte. Ltd., for a cash consideration of USD 5,001,208. The acquisition, expected to be completed by October 31, 2026, will make Gland US a direct wholly-owned subsidiary of Gland Pharma Limited, streamlining the corporate structure and removing multiple layers. Gland Pharma USA Inc., incorporated on March 7, 2022, is involved in the marketing and distribution of pharmaceutical products and had a turnover of USD 87,342 for the fiscal year ending March 31, 2025, and USD 4,83,808 for the fiscal year ending March 31, 2024.